Eric L. Simpson

22.2k total citations · 18 hit papers
333 papers, 10.9k citations indexed

About

Eric L. Simpson is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, Eric L. Simpson has authored 333 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 310 papers in Dermatology, 236 papers in Immunology and Allergy and 113 papers in Physiology. Recurrent topics in Eric L. Simpson's work include Dermatology and Skin Diseases (303 papers), Allergic Rhinitis and Sensitization (182 papers) and Asthma and respiratory diseases (112 papers). Eric L. Simpson is often cited by papers focused on Dermatology and Skin Diseases (303 papers), Allergic Rhinitis and Sensitization (182 papers) and Asthma and respiratory diseases (112 papers). Eric L. Simpson collaborates with scholars based in United States, Germany and Canada. Eric L. Simpson's co-authors include Jonathan I. Silverberg, Caroline Koudelka, Amy S. Paller, Andrew Blauvelt, Lawrence F. Eichenfield, Emma Guttman‐Yassky, Tatyana Shaw, Jon M. Hanifin, Thomas Bieber and Laurent Eckert and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Eric L. Simpson

306 papers receiving 10.6k citations

Hit Papers

Eczema Prevalence in the United States: Data from the 200... 2010 2026 2015 2020 2010 2014 2016 2021 2020 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Eczema Prevalence in the United States: Data from the 2003 National Survey of Children's Health
    2010 562 citations Eric L. Simpson et al. profile →
  2. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
    2014 471 citations Eric L. Simpson, Joanne R Chalmers et al. profile →
  3. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
    2016 415 citations Amy S. Paller, Mark Boguniewicz et al. Journal of the American Academy of Dermatology profile →
  4. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
    2021 350 citations Emma Guttman‐Yassky, Eric L. Simpson et al. profile →
  5. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
    2020 313 citations Eric L. Simpson, Andreas Wollenberg et al. profile →
  6. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis
    2021 305 citations Andrew Blauvelt, Eric L. Simpson et al. profile →
  7. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
    2020 289 citations Jonathan I. Silverberg, Eric L. Simpson et al. profile →
  8. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
    2021 287 citations Eric L. Simpson, Jonathan I. Silverberg et al. profile →
  9. Atopic dermatitis in the pediatric population
    2021 255 citations Jonathan I. Silverberg, Eric L. Simpson et al. profile →
  10. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
    2018 250 citations Emma Guttman‐Yassky, Jonathan I. Silverberg et al. Journal of the American Academy of Dermatology profile →
  11. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis
    2020 248 citations Emma Guttman‐Yassky, Andrew Blauvelt et al. profile →
  12. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies
    2021 199 citations Kim Papp, Jacek C. Szepietowski et al. Journal of the American Academy of Dermatology profile →
  13. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
    2023 162 citations Jonathan I. Silverberg, Emma Guttman‐Yassky et al. profile →
  14. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
    2022 122 citations Eric L. Simpson, Kim Papp et al. profile →
  15. The Eczema Area and Severity Index—A Practical Guide
    2022 100 citations Erin E. Grinich, M. E. Jacobson et al. Dermatitis profile →
  16. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
    2022 99 citations Emma Guttman‐Yassky, Eric L. Simpson et al. profile →
  17. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis
    2023 80 citations Amy S. Paller, Michael J. Cork et al. profile →
  18. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
    2023 72 citations Andrew Blauvelt, Jacob P. Thyssen et al. British Journal of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric L. Simpson United States 56 9.3k 7.1k 3.2k 1.9k 1.1k 333 10.9k
Eric L. Simpson United States 40 6.1k 0.7× 4.9k 0.7× 2.7k 0.8× 907 0.5× 789 0.7× 144 7.2k
Lawrence F. Eichenfield United States 57 8.9k 1.0× 5.4k 0.8× 2.1k 0.7× 1.2k 0.6× 1.5k 1.3× 448 12.2k
Andreas Wollenberg Germany 54 8.5k 0.9× 6.1k 0.9× 2.8k 0.9× 1.7k 0.9× 2.5k 2.2× 320 12.0k
Marjolein de Bruin‐Weller Netherlands 41 5.4k 0.6× 4.2k 0.6× 2.2k 0.7× 1.1k 0.6× 795 0.7× 199 6.3k
Peter Schmid‐Grendelmeier Switzerland 47 4.4k 0.5× 4.5k 0.6× 2.6k 0.8× 2.1k 1.1× 1.5k 1.3× 213 8.8k
Michael J. Cork United Kingdom 49 5.7k 0.6× 3.6k 0.5× 1.4k 0.4× 849 0.4× 1.6k 1.4× 211 8.6k
Phyllis I. Spuls Netherlands 46 5.1k 0.5× 2.7k 0.4× 1.5k 0.5× 797 0.4× 2.7k 2.3× 204 8.2k
Carla A.F.M. Bruijnzeel-Koomen Netherlands 49 4.4k 0.5× 5.5k 0.8× 2.5k 0.8× 720 0.4× 1.5k 1.3× 149 8.3k
S. Barbarot France 40 3.8k 0.4× 2.7k 0.4× 1.4k 0.4× 805 0.4× 503 0.4× 251 6.3k
Jonathan M. Spergel United States 59 4.0k 0.4× 6.7k 0.9× 3.4k 1.1× 5.6k 2.9× 3.1k 2.7× 315 15.4k

Countries citing papers authored by Eric L. Simpson

Since Specialization
Citations

This map shows the geographic impact of Eric L. Simpson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric L. Simpson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric L. Simpson more than expected).

Fields of papers citing papers by Eric L. Simpson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric L. Simpson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric L. Simpson. The network helps show where Eric L. Simpson may publish in the future.

Co-authorship network of co-authors of Eric L. Simpson

This figure shows the co-authorship network connecting the top 25 collaborators of Eric L. Simpson. A scholar is included among the top collaborators of Eric L. Simpson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric L. Simpson. Eric L. Simpson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cork, Michael J., Mette Deleuran, Bob Geng, et al.. (2025). Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age. The Journal of Allergy and Clinical Immunology In Practice. 13(5). 1164–1175.e2. 3 indexed citations
2.
Eichenfield, Lawrence F., Vimal H. Prajapati, Joseph Browning, et al.. (2025). Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( INTEGUMENT ‐ PED ): A Phase 3 Randomized Controlled Trial. Pediatric Dermatology. 42(2). 296–304. 3 indexed citations
3.
Reich, Kristian, Richard G. Langley, J.F. Silvestre, et al.. (2025). Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials. British Journal of Dermatology. 194(2). 225–235.
4.
Simpson, Eric L., Matthias Augustin, Diamant Thaçi, et al.. (2024). Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies. American Journal of Clinical Dermatology. 26(1). 121–137. 5 indexed citations
5.
Reich, Kristian, Richard G. Langley, D. Staumont‐Sallé, et al.. (2024). Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials. SKIN The Journal of Cutaneous Medicine. 8(2). s375–s375. 2 indexed citations
6.
Simpson, Eric L., Melinda Gooderham, Leon Kircik, et al.. (2024). 53652 Efficacy and safety of eblasakimab in adults with severe atopic dermatitis: a posthoc analysis of the Phase 2b TREK-AD trial. Journal of the American Academy of Dermatology. 91(3). AB194–AB194. 1 indexed citations
7.
Guttman‐Yassky, Emma, Ken Igawa, Kenji Kabashima, et al.. (2024). Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study. Dermatology and Therapy. 14(12). 3351–3366.
8.
Silverberg, Jonathan I., Lawrence F. Eichenfield, Andrew Blauvelt, et al.. (2024). 693 - Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS). British Journal of Dermatology. 191(Supplement_2). 1 indexed citations
9.
Paller, Amy S., Jonathan I. Silverberg, Michael J. Cork, et al.. (2023). The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine. 7(2). s139–s139. 1 indexed citations
10.
Reich, Kristian, Eric L. Simpson, Richard G. Langley, et al.. (2023). Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine. 7(2). s143–s143. 1 indexed citations
11.
Jacobson, M. E., R. Seshadri, Ryota Morimoto, et al.. (2023). Early intervention and disease modification in atopic dermatitis—the current state of the field and barriers to progress. Journal of the European Academy of Dermatology and Venereology. 38(4). 665–672. 4 indexed citations
12.
Wollenberg, Andreas, Leon Kircik, Eric L. Simpson, et al.. (2023). Pooled Analysis of Baricitinib Tolerability in Patients with Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events from 8 Clinical Trials. Dermatitis. 34(4). 308–314. 5 indexed citations
13.
Simpson, Eric L., Lawrence F. Eichenfield, Melinda Gooderham, et al.. (2023). 390 Efficacy and safety of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2). British Journal of Dermatology. 188(Supplement_3). 1 indexed citations
14.
Chaudhary, Prem Prashant, Portia Gough, Andrew J. Ghio, et al.. (2023). Exposure to isocyanates predicts atopic dermatitis prevalence and disrupts therapeutic pathways in commensal bacteria. Science Advances. 9(1). eade8898–eade8898. 18 indexed citations
15.
Ahn, Jiyoung, Dong Heon Lee, Chan Ho Na, et al.. (2022). Facial erythema in patients with atopic dermatitis treated with Dupilumab – a descriptive study of morphology and Aetiology. Journal of the European Academy of Dermatology and Venereology. 36(11). 2140–2152. 15 indexed citations
16.
Wollenberg, Andreas, Lisa A. Beck, Marjolein de Bruin‐Weller, et al.. (2021). Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials. British Journal of Dermatology. 186(3). 453–465. 53 indexed citations
17.
Silverberg, Jonathan I., Emma Guttman‐Yassky, Tove Agner, et al.. (2020). Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema Council. Dermatitis. 32(5). 319–326. 17 indexed citations
18.
19.
Paller, Amy S., Lawrence F. Eichenfield, Robert S. Kirsner, et al.. (2008). Three Times Weekly Tacrolimus Ointment Reduces Relapse in Stabilized Atopic Dermatitis: A New Paradigm for Use. PEDIATRICS. 122(6). e1210–e1218. 59 indexed citations
20.
Simpson, Eric L., et al.. (2002). PREVALENCE OF CONTACT ALLERGY TO BOTANICAL EXTRACTS IN PATIENTS WITH COSMETIC DERMATITIS. American Journal of Contact Dermatitis. 13(2). 90–90. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eric L. Simpson Breakdown of academic impact, for papers by Lawrence F. Eichenfield Breakdown of academic impact, for papers by Andreas Wollenberg Breakdown of academic impact, for papers by Marjolein de Bruin‐Weller Breakdown of academic impact, for papers by Peter Schmid‐Grendelmeier Breakdown of academic impact, for papers by Michael J. Cork Breakdown of academic impact, for papers by Phyllis I. Spuls Breakdown of academic impact, for papers by Carla A.F.M. Bruijnzeel-Koomen Breakdown of academic impact, for papers by S. Barbarot Breakdown of academic impact, for papers by Jonathan M. Spergel
Rankless by CCL
2026